Linear regression for the decline in eGFR in the entire cohort according to SMg quintiles (mg/dL)
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||||||||||
| β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | β | 95% CI | P value | |
| SMg quintiles | |||||||||||||||
| Q1 | −0.93 | – 1.35 to 0.50 | < 0.001 | − 0.78 | –1.22 to −0.34 | <0.001 | − 0.71 | –1.16 to −0.27 | 0.002 | − 0.64 | –1.08 to −0.20 | 0.005 | − 0.50 | –0.95 to −0.05 | 0.028 |
| Q2 | −0.41 | – 0.82 to 0.01 | 0.06 | − 0.27 | –0.70 to 0.15 | 0.21 | − 0.24 | –0.67 to 0.18 | 0.26 | − 0.21 | –0.64 to 0.21 | 0.33 | − 0.15 | –0.58 to 0.27 | 0.48 |
| Q3 | −0.25 | – 0.66 to 0.15 | 0.22 | − 0.18 | 0.60 to 0.23 | 0.39 | − 0.18 | –0.60 to 0.24 | 0.41 | − 0.15 | –0.56 to 0.27 | 0.48 | − 0.12 | –0.53 to 0.30 | 0.58 |
| Q4 | −0.27 | – 0.69 to 0.14 | 0.2 | − 0.20 | –0.62 to 0.23 | 0.36 | − 0.20 | –0.63 to 0.22 | 0.35 | − 0.17 | –0.59 to 0.26 | 0.44 | − 0.12 | –0.54 to 0.30 | 0.58 |
| Q5 | Ref. | – | – | Ref. | – | – | Ref. | – | – | Ref. | – | – | Ref. | – | – |
Model 1 was adjusted for age, gender, race/ethnicity, body mass index at DHS-1.
Model 2 was adjusted for variables in model 1 plus serum phosphorus, calcium, bicarbonate, albumin, intact parathyroid hormone, total cholesterol and high-density lipoprotein at DHS-1.
Model 3 was adjusted for variables in model 2 plus use of diuretics, dietary supplements. ACEI and ARB at DHS-1.
Model 4 was adjusted for variables in model 3 plus prevalent hypertension and CRP at DHS-1.
Model 5 was adjusted for variables in model 4 plus prevalent type 2 diabetes at DHS-1.
β, change in eGFR in reference to the highest quintile of SMg levels. eGFR was calculated according to the MDRD study equation. ΔeGFR was calculated as eGFR at D HS-2 minus eGFR at DHS-1.
ACEI, ACE inhibitors; ARB, angiotensin II receptor blockers; CRP, C reactive protein; DHS, Dallas Heart Study; eGFR, estimated glomerular filtration rate; SMg, serum magnesium.